Breast Cancer Research » Pharmaceuticals

Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis

Mon, 30 May 2011 23:23:08 +0000

Provectus Pharmaceuticals Completes Patient Accrual in Phase 2C Clinical Trial of PH-10 for Psoriasis
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals has completed patient accrual in its Phase 2C clinical trial of PH-10 for psoriasis.

OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP …

Tue, 03 May 2011 23:14:37 +0000

OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP …
REDWOOD CITY, Calif., April 28, 2011 /PRNewswire/ — OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing. OMP-18R5 is a monoclonal antibody that binds selected receptors in the Wnt signaling …

Interview With the CEO of Radient Pharmaceuticals Provides Perspective as Company Shares See Increased Volume and …

Fri, 31 Dec 2010 23:14:36 +0000

Interview With the CEO of Radient Pharmaceuticals Provides Perspective as Company Shares See Increased Volume and …
LOS ANGELES, CA–(Marketwire – 12/27/10) – During the past few sessions, shares of Radient Pharmaceuticals (AMEX: RPC – News ) have seen increased volume and appreciation in anticipation of several key developments slated to occur in the short term. In an exclusive interview with BioMedReports, the leading news portal dedicated to delivering market intelligence to the biotech and medical …

Read more on Marketwire via Yahoo! Finance

Tekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results

Mon, 22 Nov 2010 00:53:24 +0000

Tekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results
VANCOUVER, BRITISH COLUMBIA–(Marketwire – 11/15/10) – Tekmira Pharmaceuticals Corporation (TSX: TKM – News )(NASDAQ: TKMR – News ), a leader in RNA interference (RNAi) therapeutics, today announced its financial and operational results for the third quarter ended September 30, 2010. Dr. Mark J. Murray, Tekmira’s President and CEO, said, “During the third quarter we continued to advance our RNAi …

Read more on Marketwire via Yahoo! Finance

AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors

Sat, 20 Nov 2010 00:37:11 +0000

AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors
AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine in patients with certain advanced solid tumors.

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Fri, 19 Nov 2010 17:50:54 +0000

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association
Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement

Thu, 30 Sep 2010 00:38:28 +0000

Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that it has completed a private placement of Series C Convertible Preferred Stock resulting in gross proceeds of approximately $6.5 million. Â The financing, which was led by Mr.

Read more on PR Newswire via Yahoo! Finance

OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced …

Tue, 28 Sep 2010 00:40:18 +0000

OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced …
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator-sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.

Read more on CNW Group via Yahoo! Finance

AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer

Thu, 16 Sep 2010 00:41:52 +0000

AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
CAMBRIDGE, Mass.—-AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment of Michael P.

Tragara Pharmaceuticals Initiates Phase I Clinical Program For TG02

Sat, 11 Sep 2010 23:46:23 +0000

Tragara Pharmaceuticals Initiates Phase I Clinical Program For TG02
Tragara Pharmaceuticals, Inc. announced the initiation of a phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced/refractory hematologic malignancies. Tragara will conduct the study at multiple clinical centers in the United States. In vitro and in vivo data of TG02 have demonstrated biological activity against acute leukemias and multiple myeloma in …